Article List

WPRIM Management System> DCMS> Clinical and Molecular Hepatology> 2016> 22> 3

Volume: 22 Issue: 3

1. Glypican-3 level assessed by the enzyme-linked immunosorbent assay is inferior to alpha-fetoprotein level for hepatocellular carcinoma diagnosis.	Page:359—365
2. Comparison of the clinical outcomes between antiviral-naïve patients treated with entecavir and lamivudine-resistant patients receiving adefovir add-on lamivudine combination treatment.	Page:350—358
3. Obesity and hepatocellular carcinoma in patients receiving entecavir for chronic hepatitis B.	Page:339—349
4. Does obesity increase the risk of hepatocellular carcinoma in chronic hepatitis B patients?.	Page:336—338
5. Non-alcoholic fatty liver diseases: update on the challenge of diagnosis and treatment.	Page:327—335
6. The assessment of hepatocellular carcinoma risk in patients with chronic hepatitis B under antiviral therapy.	Page:319—326
7. Liver transplantation for advanced hepatocellular carcinoma.	Page:309—318
8. What we need to know when performing and interpreting US elastography.	Page:406—414
9. Histopathology of a benign bile duct lesion in the liver: Morphologic mimicker or precursor of intrahepatic cholangiocarcinoma.	Page:400—405
10. A Korean patient with Guillain-Barré syndrome following acute hepatitis E whose cholestasis resolved with steroid therapy.	Page:396—399
11. Regression of esophageal varices and splenomegaly in two patients with hepatitis-C-related liver cirrhosis after interferon and ribavirin combination therapy.	Page:390—395
12. Hepatitis B surface antigen titer is a good indicator of durable viral response after entecavir off-treatment for chronic hepatitis B.	Page:382—389
13. Decreased C-reactive protein induces abnormal vascular structure in a rat model of liver dysfunction induced by bile duct ligation.	Page:372—381
14. Immunosuppression status of liver transplant recipients with hepatitis C affects biopsy-proven acute rejection.	Page:366—371